Back HIV Prevention Pre-exposure (PrEP)

Pre-exposure Prophylaxis (PrEP)

HIV-specific Immune Responses Linked to Reduced Infection Risk in PrEP Study

People who remained HIV-negative in the iPrEx pre-exposure prophylaxis (PrEP) trial were more likely to show evidence of HIV-specific T-cell responses, and certain responses were significantly associated with reduced risk of infection, according to research published in the June 22 advance edition of Proceedings of the National Academy of Sciences. These findings suggest that natural immunity may be giving Truvada PrEP a boost in preventing HIV infection.

alt

Read more:

Use of Truvada PrEP Not Linked to Depression in iPrEx Analysis

Although depression-related symptoms were the most common severe adverse events in the iPrEx trial of HIV pre-exposure prophylaxis (PrEP) among men who have sex with men, there was no association between depression and use of Truvada (tenofovir/emtricitabine) compared to placebo, according to a report in the June 16 edition of AIDS and Behavior.
alt

Read more:

Tenofovir Alafenamide Subdermal Implant Shows Promise for HIV PrEP in Beagle Study

A sustained-release subdermal implant was able to maintain consistently high levels of tenofovir in cells with no adverse events in an animal study, offering proof-of-concept that an implant may be a good candidate for HIV pre-exposure prophylaxis, or PrEP, according to a study described in the April 20 edition of Antimicrobial Agents and Chemotherapy.

alt

Read more:

Prioritization is Crucial for the Success of PrEP, Model Confirms

A mathematical model developed by researchers at Imperial College in London, based on what would happen if pre-exposure prophylaxis (PrEP) was introduced into a high-prevalence region in Kenya, shows that PrEP could be a "runaway success" or a "runaway failure," depending on a number of factors, according to a report in the March 27 edition of AIDS. These factors include adherence, whether new longer-lasting HIV drugs are used, the cost of drugs, and the overall efficiency of distribution.

alt

Read more:

Truvada PrEP Causes Only Minimal Bone Loss, Raltegravir Easier on Bones than PIs

Use of tenofovir/emtricitabine (Truvada) for HIV pre-exposure prophylaxis (PrEP) was associated with a small decrease in bone mineral density that stabilized after the first 6 months, according to study findings reported in the April 23 edition of Clinical Infectious Diseases. Related research showed that HIV-positive people starting an antiretroviral regimen containing the integrase inhibitor raltegravir (Isentress) experienced less bone loss than those taking protease inhibitors.

alt

Read more: